APA (7th ed.) Citation

W, H., L, W., J, X., W, L., M, W., J, Y., . . . C, Q. (2022). Efficacy and safety of azathioprine, mycophenolate mofetil, and reduced dose of rituximab in neuromyelitis optica spectrum disorder. European journal of neurology, 29(8), 2343. https://doi.org/10.1111/ene.15355

Chicago Style (17th ed.) Citation

W, Huang, et al. "Efficacy and Safety of Azathioprine, Mycophenolate Mofetil, and Reduced Dose of Rituximab in Neuromyelitis Optica Spectrum Disorder." European Journal of Neurology 29, no. 8 (2022): 2343. https://doi.org/10.1111/ene.15355.

MLA (9th ed.) Citation

W, Huang, et al. "Efficacy and Safety of Azathioprine, Mycophenolate Mofetil, and Reduced Dose of Rituximab in Neuromyelitis Optica Spectrum Disorder." European Journal of Neurology, vol. 29, no. 8, 2022, p. 2343, https://doi.org/10.1111/ene.15355.